You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • FRI0380 Long-term safety of BCX4208 added to allopurinol in the chronic management of GOUT: Results of a phase 2 24-week blinded safety extension and vaccine challenge study

Citation Tools

Article menu
Download PDFPDF
Scientific Abstracts
Poster Presentations
Posters
Bone diseases other than osteoporosis, metabolic diseases and crystal diseases
FRI0380 Long-term safety of BCX4208 added to allopurinol in the chronic management of GOUT: Results of a phase 2 24-week blinded safety extension and vaccine challenge study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Hollister A, Dobo S, Maetzel A, et al
FRI0380 Long-term safety of BCX4208 added to allopurinol in the chronic management of GOUT: Results of a phase 2 24-week blinded safety extension and vaccine challenge study
Annals of the Rheumatic Diseases 2013;71:442-443.